Calidi Biotherapeutics (NYSE:CLDI) Shares Up 4.1% – Still a Buy?

Calidi Biotherapeutics, Inc. (NYSE:CLDI)’s stock price shot up 4.1% during mid-day trading on Thursday . The company traded as high as $1.30 and last traded at $1.26. 495,336 shares were traded during mid-day trading, a decline of 77% from the average session volume of 2,139,222 shares. The stock had previously closed at $1.21.

Calidi Biotherapeutics Price Performance

The business’s 50 day moving average is $1.17 and its 200-day moving average is $1.37.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in shares of Calidi Biotherapeutics by 304.0% during the fourth quarter. Geode Capital Management LLC now owns 160,018 shares of the company’s stock worth $184,000 after buying an additional 120,406 shares during the last quarter. HighTower Advisors LLC bought a new stake in shares of Calidi Biotherapeutics during the fourth quarter worth $118,000. Drive Wealth Management LLC bought a new stake in shares of Calidi Biotherapeutics during the fourth quarter worth $104,000. Virtu Financial LLC bought a new stake in shares of Calidi Biotherapeutics during the fourth quarter worth $84,000. Finally, CPR Investments Inc. grew its stake in shares of Calidi Biotherapeutics by 80.4% during the fourth quarter. CPR Investments Inc. now owns 101,000 shares of the company’s stock worth $116,000 after buying an additional 45,000 shares during the last quarter. 12.53% of the stock is owned by institutional investors.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.